Abstracts tagged "Connective tissue diseases"

Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…
Abstract Number: 698 • 2013 ACR/ARHP Annual Meeting
Adverse Events With The Use Of Radiotherapy In Patients With Connective Tissue Diseases and Cancer: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Juan A Martínez-López², Jean H. Tayar³, Mahesh Bavineni⁴ and Maria E. Suarez-Almazor⁵, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²Rheumatology, Section for Autoimmune Diseases, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³General Internal Medicine, University of Texs, MD Anderson Cancer Center, Houston, TX, ⁴Internal Medicine, Louisiana State University Lafayette, Lafayette, LA, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: In the era of modern medicine, radiotherapy remains a cornerstone for the multi-modality cancer treatment. Methods: We conducted a comprehensive search for any study…
Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Kwi Young Kang¹, Chan Hong Jeon², Sung Jae Choi³, Seung-Ki Kwok⁴, Seong-Kyu Kim⁵, Hyoun-Ah Kim⁶, Eon Jeong Nam⁷, Yong-Beom Park⁸, Kichul Shin⁹, Jaejoon Lee¹⁰, Chang-Hoon Lee¹¹, Chan-Bum Choi¹², Shin-Seok Lee¹³ and Dae-Hyun Yoo¹⁴, ¹Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, ²Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ³Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁷Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁹Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, ¹⁰Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹¹Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ¹³Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ¹⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
Abstract Number: 1499 • 2012 ACR/ARHP Annual Meeting
The Soluble Guanylate Cyclase Mediates Its Anti-Fibrotic Effects by Inhibiting TGF-β Signaling
Christian Beyer¹, Sonia C. Schindler², Alfiya Distler³, Clara Dees⁴, Helena Reichert², Hümeyra Akan², Peter Sandner⁵, Oliver Distler⁶, Georg Schett⁷ and Joerg HW Distler³, ¹Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Bayer Health Care, Global Drug Discovery – Common Mechanism Research, Bayer Health Care, Global Drug Discovery – Common Mechanism Research, Wuppertal, Germany, ⁶Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: We have recently demonstrated that stimulation of the soluble guanylate cyclase (sGC) has potent anti-fibrotic activity in different models of fibrosis. sGC stimulation increases…
Abstract Number: 197 • 2012 ACR/ARHP Annual Meeting
Collapsing Glomerulopathy in Collagen Vascular-Like Disease
Rawad Nasr¹, Christine Johns² and Elie Gertner³, ¹Rheumatology - Internal Medicine, University of Minnesota, Minneapolis, MN, ²Section of Nephrology, Regions Hospital, St Paul, MN, ³Section of Rheumatology, Regions Hospital and University of Minnesota Medical School, St. Paul, MN
Background/Purpose: Background: Collapsing Glomerulopathy (CG) is an uncommon podocytopathy with distinct clinical and pathological characteristics. It is usually associated with HIV disease or parvovirus B19…
Abstract Number: 70 • 2012 ACR/ARHP Annual Meeting
The Impact of Systemic Autoimmune Rheumatic Disease On One-Year Mortality in Congestive Heart Failure Patients: A Population-Level Analysis
Stephanie O. Keeling¹, Asvina Bissonauth¹, Becky Leung² and Padmaja Kaul², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Little is known about the prevalence of systemic autoimmune rheumatic diseases (SARDs) in patients with congestive heart failure (CHF) and its contribution to long-term…
Abstract Number: 1955 • 2012 ACR/ARHP Annual Meeting
Is the Pattern of Capillary Deposition of Complement Membrane Attack COPMLEX Useful in the Differential Diagnosis of Inflammatory?
Patrick Gordon¹, Nuria Villagra², Istvan Bodi², Andrew King², Stefan Buk², Tibor Hortobagyi² and Safa Al-Sarraj², ¹Department of Rheumatology, King's College London, London, United Kingdom, ²Department of Clinical Neuropathology, King's College Hospital, London, United Kingdom
Background/Purpose: Inflammatory myopathies are a heterogeneous group of diseases. We investigated if the location and pattern of deposition of complement membrane attack complex (MAC) can…
Abstract Number: 1824 • 2012 ACR/ARHP Annual Meeting
Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
Thomas W. Schmidt¹, Daniel F. Battafarano¹, Christopher R. Frei², Eric M. Mortensen³ and Ishak Mansi⁴, ¹Rheumatology, San Antonio Military Medical Center, San Antonio, TX, ²Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine, San Antonio Military Medical Center, San Antonio, TX
Background/Purpose: Due to their anti-inflammatory effects, statins were proposed to lower the incidence of connective tissue diseases (CTD). The objective of this study is to…
Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting
Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Lesley Ann Saketkoo¹, Dörte Huscher², Dinesh Khanna³, Paul F. Dellaripa⁴, Kevin Flaherty⁵, Chester V. Oddis⁶, Kristine Phillips⁷, Athol U. Wells⁸, Christopher P. Denton⁹, Oliver Distler¹⁰, Otylia M. Kowal-Bielecka¹¹, Romy Christmann¹², Nora Sandorfi¹³, David Pittrow¹⁴, Vibeke Strand¹⁵, James R. Seibold¹⁶, Kevin K. Brown¹⁷ and Eric L. Matteson¹⁸, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Department of Critical Care and Pulmonary Medicine, University of Michigan, Ann Arbor, MI, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ¹⁰Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ¹⁴Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, ¹⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ¹⁶Scleroderma Research Consultants LLC, Avon, CT, ¹⁷Autoimmune Lung Center, National Jewish Hospital, Denver, CO, ¹⁸Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…
Abstract Number: 1649 • 2012 ACR/ARHP Annual Meeting
French Cohort Study of 141 Cases of Autoimmune Congenital Heart Block
Kateri Levesque¹, Alice Maltret², Mohamed Hamidou³, Moez Jallouli⁴, Jean Loup Pennaforte⁵, Pauline Orquevaux⁵, Jean-Charles Piette⁶, Zahir Amoura⁴, Francois Barriere⁷, Jérome Le Bidois², Laurent Fermont², Laurence Cohen⁸, Olivier Meyer⁹, Olivier Fain¹⁰, Arnaud Theulin¹¹, Hugues Lucron¹², Francois Sassolas¹³, Holly Bezanahary¹⁴, Gaëlle Guettrot-Imbert¹⁵, Pascal Seve¹⁶, Elizabeth Diot¹⁷, Nathalie Morel¹, Christophe Deligny¹⁸, Elisabeth Villain² and Nathalie Costedoat-Chalumeau¹⁹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ³Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁴Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁵Hu Robert Debre, CHU Reims, Reims, France, ⁶Hospital Pitie, Paris, ⁷Pediatry, CHU Nantes, Nantes, France, ⁸Cardiology, Institut Jacques Cartier, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, Bondy, France, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Cardiology, CHU Fort-de-France, Fort de France, Martinique, ¹³Cardiology, CHU Lyon, Lyon, France, ¹⁴Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁵Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Internal medicine, CHU Lyon, Lyon, France, ¹⁷Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ¹⁸Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹⁹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Cardiac neonatal lupus manifestations mainly include congenital heart block (CHB), endocardial fibroelastosis and dilated cardiomyopathy. We report the preliminary results of the French registry…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].